Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits P I3 K delta
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Ukoniq
|
| gptkbp:class |
P I3 K inhibitor
|
| gptkbp:clinical_trial |
combination therapy
Phase 2 monotherapy NC T02953509 NC T03332019 NC T03610066 |
| gptkbp:contraindication |
severe liver impairment
active infection |
| gptkbp:developed_by |
TG Therapeutics
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
gptkb:2021
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Umbralisib
|
| gptkbp:indication |
gptkb:healthcare_organization
follicular lymphoma marginal zone lymphoma |
| gptkbp:ingredients |
C22 H24 Cl N3 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 XX
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:is_used_for |
treatment of certain types of lymphoma
|
| gptkbp:lifespan |
approximately 15 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
Ukoniq
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
inhibits cell proliferation
bioavailability 80% |
| gptkbp:population |
adults
|
| gptkbp:research_areas |
oncology
hematology immunology |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea diarrhea rash hypersensitivity thrombocytopenia neutropenia pneumonitis increased liver enzymes |
| gptkbp:social_structure |
sulfonamide derivative
|
| gptkbp:targets |
P I3 K pathway
|
| gptkbp:type_of |
1448500-01-4
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
5
|